QQ客服 官方微博 反馈留言

	Association of LRP1B mutation with tumor mutation burden and outcomes in melanoma and non-small cell lung cancer patients treated with immune check-point blockades
	Chen H.; Chong W.; Wu Q.; Yao Y.; Mao M.; Wang X.
刊名	Frontiers in Immunology
	2019
卷号	10期号:MAY
关键词	Immunotherapy LRP1B Melanoma Mutation signatures NSCLC Tumor mutation burden
DOI	10.3389/fimmu.2019.01113
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4546104
专题	山东大学
作者单位	Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan, China, Key Laboratory of Cancer Prevention and Therapy of Tianjin,
推荐引用方式 GB/T 7714	Chen H.,Chong W.,Wu Q.,et al. Association of LRP1B mutation with tumor mutation burden and outcomes in melanoma and non-small cell lung cancer patients treated with immune check-point blockades[J]. Frontiers in Immunology,2019,10(MAY).
APA	Chen H.,Chong W.,Wu Q.,Yao Y.,Mao M.,&Wang X..(2019).Association of LRP1B mutation with tumor mutation burden and outcomes in melanoma and non-small cell lung cancer patients treated with immune check-point blockades.Frontiers in Immunology,10(MAY).
MLA	Chen H.,et al."Association of LRP1B mutation with tumor mutation burden and outcomes in melanoma and non-small cell lung cancer patients treated with immune check-point blockades".Frontiers in Immunology 10.MAY(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。